All Oncology News

A new drug application has been submitted for MM-398 in combination with 5-fluorouracil and leucovorin for patients with metastatic pancreatic cancer following prior treatment with a gemcitabine-based therapy.

OncLive sat down with F. Stephen Hodi, director, Melanoma Center, director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, to gain further insight into combination and sequencing strategies for patients with melanoma.

The generics and specialty manufacturer Mylan has recalled several chemotherapy agents, including gemcitabine, carboplatin, methotrexate, and cytarabine, due to the presence of visible foreign particulates.

The chimeric antigen receptor T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

The FDA has approved second-line ramucirumab in combination with FOLFIRI as a treatment for patients with metastatic colorectal cancer (mCRC) following progression an upfront bevacizumab-containing regimen.

The FDA has updated the label for pomalidomide plus low-dose dexamethasone for multiple myeloma to include data from the phase III MM-003 study.

Single-agent ibrutinib demonstrated an overall response rate of 91%, including a complete response rate of 14%, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Treatment with the antibody-drug conjugate inotuzumab ozogamicin significantly extended complete hematologic remission rates compared with chemotherapy for adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia,

OncLive spoke with Elizabeth A. Mittendorf, MD, PhD, to learn more about the PRESENT trial and the potential impact of nelipepimut-S in breast cancer.

Low vitamin D levels prior to treatment may be linked to risk of relapse or death for patients with follicular lymphoma.

The FDA has granted a breakthrough therapy designation to crizotinib as a potential treatment for patients with ROS1-positive non–small cell lung cancer.

The FDA has granted a priority review to the antibody-drug conjugate brentuximab vedotin as a consolidation therapy following autologous stem cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression.

The president of Medicine & Science at Cancer Treatment Centers of America and editor-in-chief of OncologyLive magazine argues the FDA's recent approval of olaparib (Lynparza) for women with BRCA-mutated advanced ovarian cancer is too restrictive and should be offered to many more patients.

Treatment with AZD9291 at 80 mg per day elicited a response in 66% of patients with EGFR T790M-positive non–small cell lung cancer.

Nivolumab (Opdivo) improved survival versus docetaxel in patients with pretreated nonsquamous non–small cell lung cancer in the phase III CheckMate-057 trial.

Brigatinib, an investigational ALK tyrosine kinase inhibitor, demonstrated significant intracranial antitumor activity in patients with ALK-positive non–small cell lung cancer and brain metastases.

With the flourish of a pen, President Obama put an end to a yearly nightmare of congressional budget wrangling when he signed the Medical Access and CHIP Reauthorization Act of 2015, otherwise known as the Sustainable Growth Rate formula repeal.

Topline results announced today from the phase III Swedish trial 10TASQ10 demonstrated that tasquinimod failed to extend overall survival in men with metastatic castrate-resistant prostate cancer.

In an interview with OncLive, Jeffrey S. Weber, MD, PhD, discussed combinations currently in development for patients with advanced metastatic melanoma, and key considerations in employing the new therapies in clinical practice.

The PALOMA-3 trial examining a palbociclib regimen in HR+/HER2- breast cancer was halted after an independent panel determined it met the primary endpoint of improving progression-free survival.

Yale University has launched a multicenter clinical trial, sponsored by Stand Up to Cancer and Melanoma Research Alliance, that will apply the latest in personalized medicine technology to treat metastatic melanoma.

Clinical trial evidence indicates that some women with high-grade serous ovarian cancer who do not test positive for a BRCA mutation also may respond to olaparib.

The Senate has joined the House of Representatives in passing legislation to repeal the Sustainable Growth Rate (SGR) formula and replace it with the Medicare Access and CHIP Reauthorization Act of 2015 (HR 2).

Gary L. Johnson, PhD, discusses how BET bromodomain inhibitors could offer a potential solution to lapatinib resistance in patients with HER2-postive breast cancer.

M. Yair Levy, MD, discussed the impact of non-chemotherapeutic agents on the treatment of patients with NHL in an interview with OncLive.

To further understand how cytokines are used in today's landscape and what their role will be in the future, OncLive interviewed Sanjiv S. Agarwala, MD, Section Chief of Hematology/Oncology, St. Luke's Cancer Center, and professor of Medicine, Temple University.

Steven P. Treon, MD, PhD, discusses new findings from the pivotal phase II trial of ibrutinib in Waldenström's Macroglobulinemia.

The possibility of going bankrupt is high on the list of concerns for 37.1% of cancer patients.

One in five Medicare patients with melanoma waits more than 1.5 months after diagnosis to undergo surgery.

Sundar Jagannath, MD, discusses the latest research advances in myeloma, and how these steps will impact the future treatment paradigm for the disease.